Company intelligence / Profile preview

AIT Strategies

Ownership: Private
Development stage: Phase 1

Overview

AIT Strategies specializes in translational immunology, clinical development, regulatory strategy, and product development. The firm innovates in indirect immunization approaches and collaborates with academic institutions, biotech companies, and CROs to advance novel therapies—especially in cancer immunotherapy. It does not appear to have its own pipeline of therapeutics but has contributed intellectual property (notably IgE technology) that was acquired by Quest PharmaTech[1][6].

Therapeutic areas: OncologyPulmonologyImmunology
Industry: Drug Discovery Services

Drug pipeline

1 asset

AR20.5

Phase 1

Indications: Pancreatic cancer

Partnerships

Quest PharmaTech (collaboration/technology transfer)Academic collaborators

Beyond the preview

Go deeper on AIT Strategies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIT Strategies.

Explore the full profile